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with BPH in the USA, managed with watchful 
waiting or pharmacotherapy. Men enrolled in 
the BPH Registry who completed the IPSS BQ 
and the four-item BPH-II at enrolment were 
identified. The association between the IPSS 
BQ score and the BPH Impact Index was 




At baseline (enrolment visit), 6439 men (mean 
age 66 years) completed the IPSS BQ and the 




) score of the IPSS BQ 
was 2.5 (1.4) and of the BPH-II was 2.8 (2.8). 
Based on responses to the BPH-II, at least 
half the men reported that their urinary 
symptoms were associated with physical 
discomfort, worry about their health, and 
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The IPSS BQ score has a strong and positive 
correlation with the BPH-II among men 
enrolled in the BPH Registry. The IPSS BQ is a 
convenient tool for assessing disease-specific 
quality of life when determining treatment 
strategies and evaluating treatment 




benign prostatic hyperplasia, lower urinary 
tract symptoms, bother score, disease-specific 
quality of life
Study Type – Symptom prevalence study 
(inception cohort) 




To evaluate the association between the 
International Prostate Symptom Score (IPSS) 
bother question (BQ) and a validated disease-
specific quality-of-life questionnaire, the 
Benign Prostatic Hyperplasia (BPH) Impact 





The BPH Registry and Patient Survey is a 
multicentre, longitudinal, observational 
database of management practices and 




BPH is a common health problem in ageing 
men, affecting 50–80% of men aged 50–
80 years [1]. Many men with BPH develop 
moderate-to-severe LUTS, including a weak 
urinary stream, hesitancy during urination, 
straining to initiate urination, increased 
frequency of urination, nocturia, and a 
sensation of incomplete bladder emptying 
after urination, that can be bothersome and 
compromise their quality of life (QoL) [2,3]. 
The bother associated with LUTS/BPH is 
the main reason that men seek treatment, 
and a key decision point in the diagnosis 
and treatment algorithm of the AUA 
2003 guidelines on managing BPH [4]. In 
general, watchful waiting is the standard 
recommendation for men with BPH and mild 
or moderate-to-severe LUTS that are not 
bothersome, whereas watchful waiting, 
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-reductase inhibitors (5ARIs), and 
AB plus 5ARI combined, minimally invasive 
therapy, or surgical therapy are recommended 
management options for men with 
bothersome moderate-to-severe LUTS 
associated with BPH [4].
The seven-item AUA Symptom Index, 
developed and psychometrically validated by 
an AUA Measurement Committee in 1992, 
reliably assesses the severity of LUTS and is 
responsive to changes in treatment [5]. The 
eight-item IPSS, which uses the same seven 
questions assessing LUTS severity as the AUA 
Symptom Index, plus an eighth disease-
specific QoL question that assesses the bother 
associated with LUTS, was adopted by the 
WHO in 1993 [6]. The IPSS bother question 
(BQ) is the most commonly used measure of 
QoL in the evaluation of men with BPH [7]. 
Various studies have shown the reliability, 
validity and sensitivity of the IPSS BQ [5,8,9] 
and the strong positive association between 
LUTS severity and the IPSS BQ score for 
men from different countries and cultural 
backgrounds [2,9–14]. Thus, it has been 
suggested that the IPSS BQ is a simple 
and reliable tool for assessing treatment 
outcomes in men with bothersome LUTS/BPH 
[15]. To further test this hypothesis, we 
evaluated the association between the IPSS 
BQ and a validated disease-specific QoL 
instrument, the BPH Impact Index (BPH-II) [8], 





The BPH Registry and Patient Survey is a 
prospective, multicentre, longitudinal, 
observational disease registry designed to 
examine patient characteristics and outcomes 
and physician management practices in men 
with LUTS/BPH in the USA who are managed 
with watchful waiting or pharmacotherapy by 
urologists or primary-care providers. The 
registry, which was sponsored by Sanofi-
Aventis, was designed and developed by a 
20-member Steering Committee composed 
of urologists, primary-care physicians, 
psychologists and a biostatistician. A full 
description of the design of the registry was 
published previously [16]. In brief, men with 
LUTS/BPH were eligible for enrolment if they 
provided consent and were: presently/
recently treated with approved prescription 
medications for the symptoms of BPH, 
untreated (i.e. managed with watchful 
waiting or newly diagnosed), or currently 
taking botanical products. Exclusion criteria 
included lower urinary tract disease or 
carcinoma, carcinoma of the prostate, bladder 
or kidney, previous prostate surgery or 
minimally invasive procedure, isolated bladder 
neck disease or urethral stenosis/strictures, 
gross haematuria, acute urinary retention, 
neurological disease affecting urinary 
function, active kidney or liver disease, and 
use of LHRH analogues or antiandrogens.
At the baseline visit, men completed a 
demographic questionnaire and various other 
questionnaires, including the IPSS BQ [5] and 
the four-item BPH-II [8]. The IPSS BQ (‘If you 
were to spend the rest of your life with 
your urinary condition just the way it is 
now, how would you feel about that?’) had 
scores of 0 (delighted), 1 (pleased), 2 (mostly 
satisfied), 3 (mixed about equally satisfied 
and dissatisfied), 5 (mostly dissatisfied), 5 
(unhappy), and 6 (terrible), with higher scores 
indicating worse QoL. The four questions of 
the BPH-II are: (i) Over the past month, how 
much physical discomfort did any urinary 
problem cause you?; (ii) Over the past month, 
how much did you worry about your health 
because of any urinary problems?; (iii) Overall, 
how bothersome has any trouble with 
urination been during the past month?; and 
(iv) Over the past month, how much time has 
any urinary problem kept you from the kinds 
of things you would usually do? For the BPH 
Registry, each question of the BPH-II had 
scores of 0 (none/not at all), 1 (only a little/
bothers me a little), 2 (some/bothers me 
some), and 3 (a lot/all of the time), with the 
total score calculated as the sum of the scores 
of the individual questions. Therefore, for the 
BPH Registry, the total score of the BPH-II was 
0–12, with a higher score indicating worse 
QoL. Investigators collected information on 
disease history, clinical history, relevant 
concomitant medications, laboratory data, 
vital signs, and common complaints 
associated with BPH treatment.
Men enrolled in the BPH Registry who 
completed the IPSS BQ and the BPH-II at the 
baseline visit were identified. The association 
between the IPSS BQ and the BPH-II was 




Of 6909 patients enrolled in the BPH Registry 
by urologists (4537 patients) and primary-
care physicians (2372 patients) at 402 sites in 
the USA, 6439 (93%) completed both the IPSS 
BQ and the BPH-II at baseline (enrolment 
visit). The baseline demographics and clinical 
characteristics of these 6439 patients 
(Table 1) were comparable with those of the 
entire cohort of enrolled men. The median 
(range) age of the 6439 men was 67 (30–90) 
years, with 3028 (47%) not treated for 























Black/African American 603 (9)
Other 461 (7)
Median years since BPH diagnosis (5555) 3.0





No treatment 3028 (47)
AB monotherapy 2020 (31)





 5ARI 670 (10)
Anticholinergics (monotherapy or combined
therapy)
123 (2)
Other or missing data 198 (3)






Slightly enlarged 2095 (43)
Moderately enlarged 1612 (33)
Significantly enlarged 312 (6)
Median total PSA level, ng/mL (4919) 1.8
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Registry and 3213 (50%) treated with AB 





combined therapy, or anticholinergics before 
enrolment. The remaining 198 (3%) men were 
treated with other medications or their BPH 





) scores of the IPSS BQ and the 
BPH-II at baseline are listed in Table 2. Based 
on responses to the four questions of the 
BPH-II, most of the 6439 men with BPH 
reported that during the past month their 
urinary problems were associated with 
physical discomfort (3206, 50%), worry about 
their health (3194, 50%), and bothersomeness 
(4104, 64%) (Fig. 1). Only 1610 (26%) of the 
6439 men reported that any urinary problem 
kept them from doing their usual activities. 









 0.001) and positively correlated with 
the total score and the score for each of the 
four questions of the BPH-II (Table 3). The 
strongest correlations were between the IPSS 
BQ and question 3 (bothersomeness of 








 0.67) and the total 












In men with LUTS/BPH who were enrolled in 
the BPH Registry, the IPSS BQ has a significant 
and strong positive correlation with the BPH-
II [8], a validated disease-specific measure of 
QoL that is used as a measure of treatment 
outcomes in men with symptomatic BPH. The 
present results confirm a previous report of a 
strong positive association between the IPSS 








 0.62) in 4800 
men, aged 40–79 years, surveyed in the 
UrEpik study [17], and further support the 
hypothesis that the IPSS BQ is a simple 
and valid measure that can be useful for 
assessing treatment outcomes in men with 
symptomatic BPH [15]. Preliminary data from 
the BPH Registry database indicated that 
the IPSS BQ score was only weakly correlated 
with the Short Form-12, a generic QoL 
questionnaire. Using baseline data from 589 
men enrolled during the first 3 months of the 
BPH Registry, the Pearson product-moment 
correlation coefficients for the IPSS BQ score 
with the Short Form-12 physical component 
summary score and the mental component 









respectively [18]. These data suggested 
that the generic Short Form-12 might not 
adequately measure the bother associated 
with LUTS/BPH, confirming previous reports 
[7,19,20].
The bothersomeness and impact of LUTS 
on QoL is the main reason why men seek 
treatment for BPH [4,21,22]. The current 
AUA guideline on the management of BPH, 
issued in 2003, states that the impact of 
LUTS/BPH on a patient’s QoL, especially 
the bothersomeness of LUTS, should be the 
primary consideration in treatment decisions 
and in assessments of treatment response 
and disease progression [4]. Although various 
validated QoL instruments have been used 
to assess disease-specific QoL in men with 
LUTS/BPH, the IPSS BQ is the easiest to 
administer and the most widely accepted and 
used [7]. The IPSS BQ score has been used 
extensively to assess disease-specific QoL in 
placebo-controlled clinical trials evaluating 
pharmacotherapy for treating BPH. In the 
single-arm weighted average of all studies 
evaluating ABs, 5ARIs, combined therapy, or 
controls conducted by the AUA and used as a 
basis for the 2003 guideline, the IPSS BQ score 
improved (decreased) from baseline twice as 
much with ABs as with placebo, twice as 
much with combined therapy as with placebo, 
and the same with 5ARIs as with placebo in 
studies of 3–9 months’ duration [23]. These 
results suggest that ABs improve QoL more 
than 5ARIs, with AB plus 5ARI therapy 
providing no further improvement than 
AB monotherapy. Although the BPH-II was 
used to assess QoL in fewer studies of 
3–9 months’ duration than the IPSS BQ in 
the AUA single-arm weighted analysis, the 
overall trends in improvements in QoL for 
different pharmacotherapies, as assessed with 
the BPH-II, were comparable with those 
assessed with the IPSS BQ [23]. Disease-
specific QoL measures, e.g. the IPSS BQ score, 
have been shown to improve to a greater 
extent in response to BPH treatment than 




Responses to the BPH-II
questions; higher scores indicate
a greater negative impact of
urinary symptoms; percentages


























Correlation between the 
IPSS BQ score and BPH-II
 



































The QoL scores at baseline 







IPSS BQ score (range 0–6*) 2.5 (1.4)
BPH-II
Q1: Physical discomfort (score 0–3†) 0.8 (0.9)
Q2: Worry about health (score 0–3†) 0.8 (0.9)
Q3: Bothersomeness (score 0–3†) 1.0 (0.9)
Q4: Time kept from usual activities (score 0–3†) 0.3 (0.6)
Total (0–12†) 2.8 (2.8)
 
*Higher score indicates 
greater bother. †Higher 
score indicates worse QoL.
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score, which is responsive to clinical changes, 
can be useful in evaluating the efficacy of 
treatments for BPH.
In addition to the present results, various 
studies documented the validity of the IPSS 
BQ. In the formal validation of the AUA 
Symptom Index (subsequently adopted as 
the IPSS), two overall BQs were evaluated for 
their correlation with the symptom severity 
questions and with each other [5]. The overall 









 0.71) with the seven-









 0.82) [5], showing construct 
validity and internal reliability, respectively. 
The Multinational Survey of the Aging Male, 
which examined the relationship between 
LUTS and sexual dysfunction in ageing men, 
confirmed the significant association between 
LUTS severity and LUTS bother, as assessed 
with the IPSS BQ [9]. Other studies also 
confirmed this significant association 
between LUTS severity and the IPSS BQ score 
[10,24–27] and between the IPSS BQ score 
and other measures of LUTS bother [17,24]. A 
recent study of a visual analogue scale version 
of the IPSS and IPSS BQ reported a significant 
test-retest reliability of the original IPSS BQ 

















 0.67) [26]. Because the IPSS BQ 
score is directly related to LUTS severity and is 
highly correlated with other disease-specific 
QoL measures, the IPSS BQ score represents 
a valuable tool for assessing treatment 
outcomes in men with LUTS/BPH. Just as the 
assessment of LUTS severity in men with 
BPH was standardized with the IPSS, 
standardization of the assessment of disease-
specific QoL with the IPSS BQ will facilitate 
comparisons of QoL endpoints across 
different studies.
In conclusion, among men enrolled in the BPH 
Registry, the IPSS BQ, a disease-specific QoL 
measure, had a strong positive correlation 
with the total BPH-II and each of its four 
questions. These results further support the 
validity of the IPSS BQ as a convenient tool for 
assessing disease-specific QoL that can be 
used in conjunction with the IPSS when 
determining treatment strategies and 
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